Ironwood Pharmaceuticals (IRWD) Expected to Announce Earnings on Thursday

Ironwood Pharmaceuticals (NASDAQ:IRWD) is expected to be releasing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Ironwood Pharmaceuticals to post earnings of $0.32 per share and revenue of $114.8430 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.24 earnings per share for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Ironwood Pharmaceuticals had a negative return on equity of 39.65% and a net margin of 28.26%.The company had revenue of $106.51 million for the quarter, compared to analysts’ expectations of $92.11 million. On average, analysts expect Ironwood Pharmaceuticals to post $1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Ironwood Pharmaceuticals Stock Performance

Ironwood Pharmaceuticals stock opened at $4.31 on Wednesday. The company has a market capitalization of $702.79 million, a PE ratio of 7.18 and a beta of 0.20. Ironwood Pharmaceuticals has a fifty-two week low of $0.75 and a fifty-two week high of $5.78. The firm has a 50 day moving average price of $3.87 and a 200 day moving average price of $3.97.

Insider Activity at Ironwood Pharmaceuticals

In other news, insider Ronald Silver sold 127,890 shares of the company’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $4.52, for a total transaction of $578,062.80. Following the sale, the insider owned 313,680 shares of the company’s stock, valued at approximately $1,417,833.60. This represents a 28.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Julie Mchugh sold 21,571 shares of the stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $3.73, for a total value of $80,459.83. Following the completion of the sale, the director owned 250,749 shares in the company, valued at approximately $935,293.77. The trade was a 7.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 9.30% of the company’s stock.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Several large investors have recently bought and sold shares of IRWD. Hsbc Holdings PLC acquired a new position in shares of Ironwood Pharmaceuticals during the fourth quarter worth about $79,000. Focus Partners Wealth raised its holdings in Ironwood Pharmaceuticals by 29.3% in the third quarter. Focus Partners Wealth now owns 44,652 shares of the biotechnology company’s stock valued at $58,000 after acquiring an additional 10,105 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Ironwood Pharmaceuticals in the first quarter valued at approximately $57,000. Abel Hall LLC purchased a new position in Ironwood Pharmaceuticals in the fourth quarter worth approximately $56,000. Finally, Bridgeway Capital Management LLC lifted its stake in Ironwood Pharmaceuticals by 141.9% in the second quarter. Bridgeway Capital Management LLC now owns 75,000 shares of the biotechnology company’s stock worth $54,000 after acquiring an additional 44,000 shares during the last quarter.

Wall Street Analyst Weigh In

IRWD has been the subject of several research analyst reports. Zacks Research lowered Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 30th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a report on Friday, July 24th. Finally, Wall Street Zen raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Sunday, May 17th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Ironwood Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $6.23.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.